UY35350A - Pirimidinas condensadas sustituidas con trifluorometilo y su uso - Google Patents
Pirimidinas condensadas sustituidas con trifluorometilo y su usoInfo
- Publication number
- UY35350A UY35350A UY0001035350A UY35350A UY35350A UY 35350 A UY35350 A UY 35350A UY 0001035350 A UY0001035350 A UY 0001035350A UY 35350 A UY35350 A UY 35350A UY 35350 A UY35350 A UY 35350A
- Authority
- UY
- Uruguay
- Prior art keywords
- trifluorometilo
- pyrimidins
- condensed
- replaced
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a novedosas pirimidinas condensadas sustituidas con trifluorometil o, a procedimientos para su preparación, a su uso solos o en combinación para el tratamiento y/o la profilaxis de enfermedades, y a su uso para prod ucir medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular para el trat amiento y/o la profilaxis de trastornos cardiovas culares.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13157434 | 2013-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35350A true UY35350A (es) | 2014-09-30 |
Family
ID=47826961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035350A UY35350A (es) | 2013-03-01 | 2014-02-26 | Pirimidinas condensadas sustituidas con trifluorometilo y su uso |
Country Status (28)
Country | Link |
---|---|
US (1) | US9266871B2 (es) |
EP (1) | EP2961755B1 (es) |
JP (1) | JP2016510010A (es) |
KR (1) | KR20150121007A (es) |
CN (1) | CN105308055B (es) |
AP (1) | AP2015008637A0 (es) |
AR (1) | AR094943A1 (es) |
AU (1) | AU2014222739A1 (es) |
BR (1) | BR112015020298A2 (es) |
CA (1) | CA2902993A1 (es) |
CL (1) | CL2015002343A1 (es) |
CR (1) | CR20150448A (es) |
CU (1) | CU20150095A7 (es) |
DO (1) | DOP2015000185A (es) |
EA (1) | EA027689B1 (es) |
HK (1) | HK1220974A1 (es) |
IL (1) | IL240637A0 (es) |
MA (1) | MA38365A1 (es) |
MX (1) | MX2015010966A (es) |
NI (1) | NI201500117A (es) |
PE (1) | PE20151755A1 (es) |
PH (1) | PH12015501703A1 (es) |
SG (1) | SG11201505974VA (es) |
TN (1) | TN2015000370A1 (es) |
TW (1) | TW201443066A (es) |
UY (1) | UY35350A (es) |
WO (1) | WO2014131760A1 (es) |
ZA (1) | ZA201505911B (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR201816146T4 (tr) | 2009-11-27 | 2018-11-21 | Adverio Pharma Gmbh | Meti̇l-{4,6-di̇ami̇no-2-[1-(2-florobenzi̇l)-1h-pi̇razolo[3,4-b]pi̇ri̇di̇n-3-i̇l]pi̇ri̇mi̇di̇n-5-i̇lmeti̇l}karbamatin farmasöti̇k etken madde olarak kullanima yöneli̇k olarak üreti̇lmesi̇ne yöneli̇k yöntem. |
PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
EP2822951B1 (de) | 2012-03-06 | 2017-07-26 | Bayer Intellectual Property GmbH | Substituierte azabicyclen und ihre verwendung |
MX2016000258A (es) | 2013-07-10 | 2016-04-28 | Bayer Pharma AG | Bencil-1h-pirazolo[3,4-b]piridinas y su uso. |
EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
TN2017000465A1 (en) | 2015-05-06 | 2019-04-12 | Bayer Pharma AG | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
WO2017121692A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | Substituierte sulfamide und ihre verwendung |
WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
EP3609883B1 (en) | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
EA202091020A1 (ru) | 2017-10-24 | 2020-07-24 | Байер Акциенгезельшафт | Замещенные имидазопиридинамиды и их применение |
EP3793553A1 (en) | 2018-05-15 | 2021-03-24 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
JP7542518B2 (ja) | 2018-07-11 | 2024-08-30 | ティセント セラピューティクス インコーポレーテッド | ミトコンドリア(mitochonrial)障害の処置のためのsGC刺激剤の使用 |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
EP1333833B1 (en) | 2000-10-23 | 2011-08-24 | GlaxoSmithKline LLC | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compound for the treatment of CSBP/p38 kinase mediated diseases |
AU2002221827A1 (en) | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
CA2521695C (en) | 2003-05-09 | 2011-08-16 | Asahi Glass Company, Limited | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt |
CN100355732C (zh) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
DE102007027799A1 (de) * | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte Furopyrimidine und ihre Verwendung |
AU2008282156B2 (en) | 2007-07-31 | 2014-07-17 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
US8741910B2 (en) | 2008-11-25 | 2014-06-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
US20130178475A1 (en) | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
MX2012013774A (es) | 2010-05-27 | 2012-12-17 | Merck Sharp & Dohme | Activadores de guanilato ciclasa soluble. |
CA2803688A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
EP2590987B1 (de) | 2010-07-09 | 2016-03-09 | Bayer Intellectual Property GmbH | Annellierte 4-aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
CA2833698A1 (en) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoroalkyl-substituted pyrazolopyridines and use thereof |
EP2705037B1 (de) | 2011-05-06 | 2016-06-22 | Bayer Intellectual Property GmbH | Substituierte imidazopyridine und imidazopyridazine und ihre verwendung |
MX2014000029A (es) * | 2011-07-06 | 2014-02-17 | Bayer Ip Gmbh | Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de guanilato ciclasas solubles. |
JP6096778B2 (ja) | 2011-09-01 | 2017-03-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピロロピラジンキナーゼ阻害剤 |
CN104039784B (zh) * | 2011-09-02 | 2017-08-22 | 拜耳知识产权有限责任公司 | 取代的增环嘧啶及其用途 |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
EP2822951B1 (de) | 2012-03-06 | 2017-07-26 | Bayer Intellectual Property GmbH | Substituierte azabicyclen und ihre verwendung |
-
2014
- 2014-02-25 KR KR1020157023272A patent/KR20150121007A/ko not_active Application Discontinuation
- 2014-02-25 CN CN201480011911.2A patent/CN105308055B/zh not_active Expired - Fee Related
- 2014-02-25 CA CA2902993A patent/CA2902993A1/en not_active Abandoned
- 2014-02-25 MX MX2015010966A patent/MX2015010966A/es unknown
- 2014-02-25 MA MA38365A patent/MA38365A1/fr unknown
- 2014-02-25 SG SG11201505974VA patent/SG11201505974VA/en unknown
- 2014-02-25 EP EP14706592.4A patent/EP2961755B1/de active Active
- 2014-02-25 AP AP2015008637A patent/AP2015008637A0/xx unknown
- 2014-02-25 PE PE2015001805A patent/PE20151755A1/es not_active Application Discontinuation
- 2014-02-25 BR BR112015020298A patent/BR112015020298A2/pt active Search and Examination
- 2014-02-25 EA EA201591616A patent/EA027689B1/ru not_active IP Right Cessation
- 2014-02-25 JP JP2015559484A patent/JP2016510010A/ja active Pending
- 2014-02-25 WO PCT/EP2014/053636 patent/WO2014131760A1/de active Application Filing
- 2014-02-25 AU AU2014222739A patent/AU2014222739A1/en not_active Abandoned
- 2014-02-26 TW TW103106390A patent/TW201443066A/zh unknown
- 2014-02-26 UY UY0001035350A patent/UY35350A/es not_active Application Discontinuation
- 2014-02-28 AR ARP140100657A patent/AR094943A1/es unknown
- 2014-02-28 US US14/194,224 patent/US9266871B2/en not_active Expired - Fee Related
-
2015
- 2015-07-31 PH PH12015501703A patent/PH12015501703A1/en unknown
- 2015-08-06 DO DO2015000185A patent/DOP2015000185A/es unknown
- 2015-08-17 ZA ZA2015/05911A patent/ZA201505911B/en unknown
- 2015-08-18 IL IL240637A patent/IL240637A0/en unknown
- 2015-08-21 CL CL2015002343A patent/CL2015002343A1/es unknown
- 2015-08-27 CR CR20150448A patent/CR20150448A/es unknown
- 2015-08-28 NI NI201500117A patent/NI201500117A/es unknown
- 2015-08-31 TN TN2015000370A patent/TN2015000370A1/en unknown
- 2015-09-01 CU CUP2015000095A patent/CU20150095A7/es unknown
-
2016
- 2016-08-01 HK HK16109125.1A patent/HK1220974A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN105308055B (zh) | 2017-07-14 |
CN105308055A (zh) | 2016-02-03 |
DOP2015000185A (es) | 2015-11-15 |
NI201500117A (es) | 2016-02-15 |
EP2961755A1 (de) | 2016-01-06 |
EP2961755B1 (de) | 2017-10-18 |
JP2016510010A (ja) | 2016-04-04 |
PH12015501703A1 (en) | 2015-10-12 |
CU20150095A7 (es) | 2016-02-29 |
EA201591616A1 (ru) | 2016-04-29 |
US9266871B2 (en) | 2016-02-23 |
TW201443066A (zh) | 2014-11-16 |
US20140249168A1 (en) | 2014-09-04 |
WO2014131760A1 (de) | 2014-09-04 |
CA2902993A1 (en) | 2014-09-04 |
AP2015008637A0 (en) | 2015-08-31 |
AR094943A1 (es) | 2015-09-09 |
KR20150121007A (ko) | 2015-10-28 |
MA38365A1 (fr) | 2017-09-29 |
CR20150448A (es) | 2016-01-11 |
ZA201505911B (en) | 2016-10-26 |
SG11201505974VA (en) | 2015-09-29 |
TN2015000370A1 (en) | 2017-01-03 |
BR112015020298A2 (pt) | 2017-07-18 |
MX2015010966A (es) | 2016-04-04 |
CL2015002343A1 (es) | 2016-08-12 |
HK1220974A1 (zh) | 2017-05-19 |
IL240637A0 (en) | 2015-09-24 |
PE20151755A1 (es) | 2015-12-04 |
AU2014222739A1 (en) | 2015-09-03 |
EA027689B1 (ru) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35350A (es) | Pirimidinas condensadas sustituidas con trifluorometilo y su uso | |
CU20140082A7 (es) | Pirimidinas y triazinas fusionadas sustituidas y sus uso | |
GT201200250A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
DOP2015000246A (es) | Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares | |
ECSP13012379A (es) | Pirimidinas y triazinas condensadas y su uso | |
PA8770101A1 (es) | Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso | |
GT201400033A (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
DOP2014000255A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
CR20150020A (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
GT201100205A (es) | Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido | |
CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
DOP2016000076A (es) | Tienouracilcarboxamidas cíclicas y usos de las mismas | |
UY35746A (es) | Derivados de fenilalanina sustituidos | |
CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
CR20120445A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
CL2015000072A1 (es) | Compuestos derivados de azaindol, inhibidores pi3k; metodo de preparacion; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento de tratornos inmunologicos, cancer y enfermedades cardiovasculares. | |
CO6670570A2 (es) | Pirimidinadas y tirazinas condensadas y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20211110 |